For Research

The gold standard ’omics for the research community.

Visit our website for researchers

NGH Lab 30

Our technology is trusted by researchers worldwide.

Advances in healthcare are built on medical research, with new discoveries tested and re-tested over time. We're proud to support this critical work: researchers from around the world have used our technology in over 600 peer-reviewed publications, contributing to significant medical breakthroughs and reproducible science. This rigorous process ensures that new findings are not only credible but can be reliably built upon to enhance patient care worldwide.

We've analyzed the world's largest cohorts.

UK Biobank
500,000 samples
Estonian Biobank​
200,000 samples
Finnish National Biobank​
40,000 samples
Mexico City Prospective Study​
150,000 samples
BELIEVE (Bangladesh)
50,000 samples
Uganda Genome Resource Norwegian HUNT study Copenhagen General
Population Study (DK)
Rotterdam Study (NL) INTERVAL
blood donors (UK)​
TWINS-UK PREDIMED plus (Spain)
China Kadoorie Biobank Hong Kong
Birth Cohort of 1997
Healthy Twin Study Korea Singapore Chinese Cohort Mass General Brigham
Biobank (USA)
ARIC Study (USA)

The broadest panel of blood markers in the home-testing industry.

In addition to providing groundbreaking disease risk detection, Nightingale’s Remote Health Check delivers the industry’s broadest panel of blood markers with clinical grade quality. The panel includes around 30 well-known blood markers, such as cholesterol levels, extended lipid profile, fatty acids, amino acids, sugar metabolism, and inflammation.

Nightingale’s technology has been used to analyze more than two million samples, including world-leading open-access resources like the UK Biobank. We are the only 'omics measured on every sample in the UK Biobank's extensive cohort, enabling studies into cardiovascular diseases, diabetes, liver diseases, kidney diseases, lung diseases, aging, cancer, and more, paving the way for breakthroughs in prevention and care.

Convincing science brings healthcare benefits faster.

This foundation of peer-reviewed research and analysis of massive patient cohorts has enabled the development of highly precise disease risk predictions. Because Nightingale's technology is clinically validated, the path from discovery to translation of those predictions has been dramatically shortened, and is in use to manage chronic diseases today. The research-based origins of our technology live today as tangible solutions utilized in national healthcare.

Our products for research use.

We offer analysis services globally for researchers.

CoreMetabolomics

Blood and urine analysis service for metabolomics profiles

Read more about CoreMetabolomics

RemoteOmics

Remote blood sampling and analysis service for multi-omics profiles

Read more about RemoteOmics

Visit our website for researchers.

Visit our website for researchers